Searchable abstracts of presentations at key conferences in endocrinology

ea0065p398 | Thyroid | SFEBES2019

Thyroid function testing in the first trimester of pregnancy – no role for screening?

Scott Rebecca , Agbabiaka Abigail , Agha-Jaffar Rochan

Background: Normal maternal thyroid function is essential for optimal fetal neurological development. However, targeted screening for thyroid dysfunction in the first trimester of pregnancy, together with the criteria that should be applied, remains controversial.Aim: To determine the efficacy of targeted screening for discovering new cases of thyroid dysfunction in pregnancy.Method: All women who delivered their babies at Imperial...

ea0062p70 | Poster Presentations | EU2019

How low can you go? Isolated hypothyroxinaemia in pregnancy

Scott Rebecca , Jarvis Sheba , Frise Charlotte

Case history: A 40-year-old, primaparous woman was referred at 24 weeks’ gestation to Obstetric Medicine for review of abnormal thyroid function tests (TFTs).Investigations: One year prior to pregnancy, TFTs included a thyroid stimulating hormone (TSH) level of 0.95 mU/l (local non-pregnant reference range 0.3–4.2 mU/l) and a free thyroxine level (fT4) of 7.3 mU/l (local non-pregnant reference range 9.0–23.0 mU/l). At 18 weeks’ gestat...

ea0065p47 | Adrenal and Cardiovascular | SFEBES2019

Hypokalaemic cardiac arrest – a rare presentation of primary aldosteronism

Siddiqui Mohsin , Mohan Chithra , Scott Rebecca , Wernig Florian , Hatfield Emma

A 58 year old female, with a 15 year history of hypertension and recent poor control, was admitted to the emergency department after an out of hospital cardiac arrest due to ventricular fibrillation requiring DC cardioversion. Initial investigations showed a metabolic alkalosis with profound hypokalaemia at 1.7 mmol/l. In view of lateral ST depression on the ECG post-resuscitation, she underwent an urgent coronary angiogram which demonstrated unobstructed coronary arteries. Wh...

ea0065p220 | Metabolism and Obesity | SFEBES2019

GLP-1/Glucagon dual agonist affects amino acid metabolism

Scott Rebecca , Hope David , Owen Bryn , Bloom Steve , Tan Tricia

Background: GLP-1/glucagon dual agonists are being developed as treatments for obesity due to their combined effect of reducing food intake while increase energy expenditure. Though the effect of the dual agonist on carbohydrate and lipid metabolism is well studied, little is known about the effects on protein metabolism. This study aimed to examine the acute and chronic effects of the GLP-1/glucagon dual agonist on amino acid metabolism.Methods: The lon...

ea0021p101 | Clinical practice/governance and case reports | SFEBES2009

Utilising combined treatment modalities in non-islet cell tumour hypoglycaemia (NICTH)

Agha-Jaffar Rochan , Scott Rebecca , Lok Si Chong , Cohen Mark

Non-islet cell tumour hypoglycaemia (NICTH) is a rare paraneoplastic phenomenon and there is limited guidance regarding different treatment modalities.We present two cases of NICTH focusing on the combined methods used to control hypoglycaemia.The first involves an 89-year-old gentleman diagnosed with a pelvic leiomyoma in 2003. For several years, he had experienced recurrent collapses which briefly improved following tumour emboli...

ea0021p297 | Pituitary | SFEBES2009

Should we take macroprolactinoma patients off dopamine agonists at 3 or 5 years as they almost invariably recur?

Scott Rebecca , Barber Thomas , Kenkre Julia , Garnet Catherine , Wass John

Objective: Our objective was to examine recurrence of hyperprolactinaemia following discontinuation of dopamine agonist (DA) therapy in patients with macroprolactinoma who have had treatment for 3–15 years.Methods: We identified retrospectively adult patients (n=15) attending OCDEM (Churchill Hospital, Oxford, UK) with a confirmed diagnosis of macroprolactinoma (established during the last 25 years), who had been treated with DA therapy for a...

ea0082p9 | Poster Presentations | SFEEU2022

Late local recurrence of an adrenal tumour presenting with Cushing’s disease

Yamamoto Thomsen Anna , Morganstein Daniel , Smellie James , Nichol David , Scott Rebecca

Section 1: Case history: A 68 year old lady presented with a 2 week history of pedal swelling, with large blisters appearing on her feet. Her past medical history included adrenal Cushing”s treated with a right laparoscopic adrenalectomy on a 4.7x5.2 cm lipid poor adenoma 12 years previously; she had been discharged 7 years ago after repeated normal overnight dexamethasone suppression tests. Over the last year she had gained 12 kg in weight and been diagnosed with type 2 ...

ea0077op4.4 | Metabolism, Obesity and Diabetes | SFEBES2021

Audit of Clinical Outcomes with Dexamethasone in Patients Hospitalised with COVID-19

Narendranathan Divani , Richards Molly , Cassin-Scott Rebecca , Chia Eng Pei , Distaso Walter , Tan Tricia , Izzy-Engbeaya Chioma , Salem Victoria

Background: Dexamethasone significantly improved outcomes in patients requiring supplementary oxygen and in ventilated patients with COVID-19 in the RECOVERY trial. Consequently, dexamethasone is now routinely used in these patients. However, dysglycaemia is commonly associated with steroid use and is an established risk factor for poorer outcomes in COVID-19. In this study, we aimed to elucidate the effect of dexamethasone use in patients hospitalised with COVID-19 in a real-...

ea0077p186 | Metabolism, Obesity and Diabetes | SFEBES2021

Predictors of adverse outcomes in COVID-19: A retrospective cohort study comparing the first two waves of COVID-19 hospital admissions in London, with a focus on diabetes

Hashmi Durreshahwar , Shaikhali Yusuf , Cassin-Scott Rebecca , Eng Pei , Distaso Walter , Tan Tricia , Salem Victoria , Izzy-Engbeaya Chioma

Introduction: Diabetes has been associated with poorer outcomes with COVID-19 infection, but precise predictors of mortality in patients with diabetes remain unclear. We assessed predictors of adverse outcomes in patients hospitalised with COVID-19 in Imperial College Healthcare NHS Trust (ICHNT) hospitals during the first and second waves of COVID-19 to determine if outcomes for patients with diabetes have evolved with new variants and treatments.Method...

ea0065p321 | Neuroendocrinology | SFEBES2019

A suprasellar germ cell tumour presenting with cranial diabetes insipidus

Samarasinghe Suhaniya , Scott Rebecca , Seckl Michael J , Gonzalez Mike , Harvey Richard , Unsworth Nick , Hatfield Emma , Martin Niamh , Meeran Karim

A 30-year-old female presented to her general practitioner with a three-month history of fatigue, visual disturbance, polydipsia and dizziness. She was treated for iron deficiency anaemia, but re-presented two-months later with new-onset headache and worsening visual disturbance. Previously, she had childhood leukaemia, treated in Brazil with no cranial irradiation. On examination there was left eye loss of light/dark perception and right temporal vision loss. She was referred...